Clinical trial
A Multicenter Clinical Study of Carralizumab Combined With Albumin Paclitaxel and Apatinib Mesylate in the Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
NCT05653817 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Clinical Study of Carralizumab Combined With Albumin Paclitaxel and Apatinib Mesylate in the Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong University
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- January 31, 2023
- Completion date
- January 31, 2026
- Enrollment
- 60 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.